AbbVie Acquires Nimble Therapeutics for $200M, Expanding Oral Immunology Pipeline
Key Insights
AbbVie (search) announces $200 million acquisition of Nimble Therapeutics (search), gaining access to novel oral peptide drug platform and pipeline targeting immune diseases.
Nimble's lead candidate is an oral IL-23 (search) inhibitor in preclinical development, potentially offering a non-injectable alternative to existing treatments like Skyrizi for psoriasis (search) and IBD.
The acquisition marks AbbVie (search)'s third immunology-focused buyout this year, strengthening their position in the competitive autoimmune disease market.
AbbVie (search) has announced the acquisition of Nimble Therapeutics (search) for $200 million, marking a strategic move to expand its immunology portfolio with novel oral peptide therapeutics. The deal includes additional interim funding payments and potential milestone-based compensation for Nimble shareholders.
The Madison, Wisconsin-based biotech company, originally a Roche spinout, has developed a proprietary platform for synthesizing, screening, and optimizing peptide-based drug candidates. This technology acquisition significantly bolsters AbbVie (search)'s capabilities in developing innovative immunological treatments.
Pipeline and Technology Focus
At the forefront of Nimble's pipeline is an oral IL-23 (search) inhibitor, currently in preclinical development. This candidate aims to match the potency of injectable IL-23 inhibitors while offering the convenience of oral administration and an extended half-life. The development represents a potential breakthrough in the treatment landscape currently dominated by injectable therapies such as AbbVie (search)'s Skyrizi, Johnson & Johnson's Tremfya, and Eli Lilly's Omvoh.
The company's pipeline also includes promising candidates for generalized myasthenia gravis (search) targeting C5 (search) signaling and an inflammatory bowel disease (search) treatment focusing on TL1A (search) inhibition. These programs complement AbbVie (search)'s existing immunology portfolio and research initiatives.
Strategic Significance
"The addition of Nimble's pipeline to AbbVie (search)'s existing pipeline, combined with our deep clinical and translational expertise in immunology, represents an important growth opportunity," stated Jonathon Sedgwick, AbbVie's global head of discovery research.
This acquisition follows the industry's broader trend of increased investment in immune system regulation therapies. The oral IL-23 (search) inhibitor space has already shown promise, with Johnson & Johnson and Protagonist Therapeutics recently reporting significant efficacy in Phase 3 trials of their oral candidate, icotrokinra, for psoriasis (search) treatment.
Company Background
Nimble Therapeutics (search), established in 2019 as a Roche spinout, has maintained strong industry connections, including ongoing research collaborations with Genentech. The company secured initial funding from Roche's venture arm and Telegraph Hill Partners, building on the expertise of its leadership team, many of whom previously held positions at Roche.
Market Impact
The acquisition strengthens AbbVie (search)'s position in the competitive immunology market, particularly in the development of oral alternatives to existing injectable therapies. This move aligns with the growing demand for more convenient treatment options while maintaining therapeutic efficacy in managing chronic immune conditions.